Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11819234 | 0.91 | SMN1; SMN2 (0.50) | SMN1; SMN2MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL1829260 | 0.80 | MAPT (0.58) | MEN1KMT2AMAPTALDH1A1POLB | |
| SCHEMBL11109892 | 0.80 | KDM4E (0.40) | SMN1; SMN2MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL11114830 | 0.79 | KMT2A (0.41) | MEN1KMT2AMAPTALDH1A1POLB | |
| SCHEMBL11113990 | 0.79 | OPRM1 (0.47) | SMN1; SMN2MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL11112128 | 0.79 | ADRA2A (0.43) | MEN1KMT2AMAPTALDH1A1POLB | |
| SCHEMBL11113040 | 0.79 | DRD2 (0.40) | SMN1; SMN2MEN1KMT2AMAPTKDM4E | |
| SCHEMBL85903 | 0.77 | ALOX5 (0.55) | SMN1; SMN2MEN1KMT2AMAPTTSHR | |
| SCHEMBL19327260 | 0.77 | ADRA1A (0.49) | — | |
| SCHEMBL19340062 | 0.76 | SMN1; SMN2 (0.50) | SMN1; SMN2MEN1KMT2AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124503-B2 | Compositions and methods for acylating lactams | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-09-21 | — | — | US | disclosed |
| US-20190077796-A1 | COMPOSITIONS AND METHODS FOR ACYLATING LACTAMS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2019-03-14 | — | — | US | disclosed |
| US-10040784-B2 | Compositions and methods for acylating lactams | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-08-07 | — | — | US | disclosed |
| US-20170260172-A1 | COMPOSITIONS AND METHODS FOR ACYLATING LACTAMS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2017-09-14 | — | — | US | disclosed |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-20120028920-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-02-02 | — | — | US | disclosed |
| US-8071600-B2 | Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-12-06 | — | — | US | disclosed |
| US-8071600-B2 | Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-12-06 | — | — | US | disclosed |
| EP-2287162-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | Otsuka Pharmaceutical Co., Ltd. (JP) | 2011-02-23 | — | — | EP | disclosed |
| EP-2287161-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | Otsuka Pharmaceutical Co., Limited (JP) | 2011-02-23 | — | — | EP | disclosed |
| EP-2284169-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | Otsuka Pharmaceutical Co., Limited (JP) | 2011-02-16 | — | — | EP | disclosed |
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-10-22 | — | — | US | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124503-B2 | Compositions and methods for acylating lactams | COASY, ASNS, NAAA | SMN1; SMN2 2602/4885MEN1 1331/4885KMT2A 1003/4885 |
| US-20120028920-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, GRIN2B, PMP22 | SMN1; SMN2 311/4885MEN1 2715/4885KMT2A 480/4885 |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, GRIN2B, PMP22 | SMN1; SMN2 311/4885MEN1 2715/4885KMT2A 480/4885 |
| US-20170260172-A1 | COMPOSITIONS AND METHODS FOR ACYLATING LACTAMS | COASY, NAAA, ASNS | SMN1; SMN2 2690/4885MEN1 1909/4885KMT2A 979/4885 |
| US-10040784-B2 | Compositions and methods for acylating lactams | COASY, NAAA, ASNS | SMN1; SMN2 2690/4885MEN1 1909/4885KMT2A 979/4885 |
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | GRIN2C, GRIN2B, PMP22 | SMN1; SMN2 311/4885MEN1 2715/4885KMT2A 480/4885 |
| US-20190077796-A1 | COMPOSITIONS AND METHODS FOR ACYLATING LACTAMS | COASY, NAAA, ASNS | SMN1; SMN2 2690/4885MEN1 1909/4885KMT2A 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.